Traws Pharma, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 17
- Market Cap
- -
- Website
- http://www.trawspharma.com
Clinical Trials
66
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (61 trials with phase data)• Click on a phase to view related trials
A Clinical Study Aiming to Assess Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TRX-100 in Healthy Volunteers
- First Posted Date
- 2025-01-03
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT06757738
- Locations
- 🇦🇺
Scientia Clinical Research, Sydney, Greater Sydney Area, Australia
Evaluation Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-0060 in Healthy Volunteers
- First Posted Date
- 2024-05-07
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT06402136
- Locations
- 🇦🇺
Scientia Clinical Research, Sydney, Greater Sydney Area, Australia
Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies
- Conditions
- Endometrioid Endometrial Cancer
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05705505
- Locations
- 🇺🇸
Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States
🇺🇸Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States
🇺🇸Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola, New York, United States
Study of ON 123300 in Patients With Advanced Cancer
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04739293
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸Greenville Health System, Institute for Oncology Clinical Research, Greenville, South Carolina, United States
🇺🇸Mary Crowley Cancer Research, Dallas, Texas, United States
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
- Conditions
- Myelodysplastic SyndromeRAEBRefractory Anemia With Excess BlastsMDS
- Interventions
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 372
- Registration Number
- NCT02562443
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next